Displaying 1–25 of 119 results for Emil Ciurczak, Contributing Editor

Sort By Relevance Sort By Date
1 2 3 4 5

Looking Towards the Future

(Article)

A review of IFPAC Annual Meeting 2018 from contributing editor Emil W. Ciurczak.

Product Focus: Process Analytical Technologies

(Article)

Interviews with product experts about select hardware/software products applicable to PAT/QbD, highlighting key features of each instrument/program

Henry Ford Had It Right

(Article)

Hand-made to assembly lines, now, to automated production

From ‘I Think I Can’ to ‘I Knew I Could’

(Article)

A new attitude was clearly on display at IFPAC 2017

Wish List, Predictions for 2017

(Article)

Trends include continuous manufacturing, biosimilars, supply chain security and smaller instrumentation

Pros and Cons of Biosimilars

(Article)

There are a number of points of view and opinions on how good or necessary biosimilars actually are

A Look Back at Packaging

(Article)

Packaging does much more than serve as a place for the label

Ready, Aim, Aim, Aim … Still Aiming

(Article)

Why so many pharmaceutical companies can’t “just do” PAT

What’s New in Dosage Form Analysis?

(Article)

Or, what have we forgotten?

IFPAC 2016 Conference

(Article)

Neither rain, nor sleet, nor snow could keep me from finding the lastest technology at IFPAC 2016 conference.

Toward Real-Time Release at Rutgers

(Article)

The Continuous Manufacturing (CM) program at Rutgers University continues

BRIEF: Advances in Process Analytical Technologies

(Article)

Instrument and PAT vendors are continually innovating, unveiling new systems or significant new features at PittCon

Advances in Process Analytical Technologies

(Article)

Instrument and PAT vendors are continually innovating, and 2015 is no different

Where Is Biopharma in the PAT Picture?

(Article)

The quest for “knowing exactly what’s in the soup”

Taking a Closer Look at ICH Q2 (R1)

(Article)

PAT groups must improvise when validating a process analysis. In many cases, several metrics are not based on current practices

Pursuing Solid-Dose-Processing Quality

(Article)

Complexity and lean staff often create a non-compliant operational culture; fortunately there are ways to fight the malaise

FDA’s Got It Right on Biosimilars

(Article)

U.S. regulators want more than release tests to prove biosimilar safety and efficacy

IFPAC and the ‘State-of-the-Art’ in PAT

(Article)

Time, space, utilities and labor ARE all saved by using continuous manufacturing in lieu of current production methods.

Better Data, Better Solid Dose QbD

(Article)

Newer monitoring technologies can provide real insight into solid-dose forms in process

Orphan Diseases and the Profit Margin

(Article)

Efficiencies from well applied PAT and QbD principles have the potential to re-align orphan drug cost structures

Interesting Change Coming to the FDA

(Article)

U.S. regulators are telegraphing plans to reorganize, bucking its resistance-to-change zeitgeist

I’m from the Government: Here to Help

(Article)

Conflicting goals between the FDA and Congress are creating an interesting “tug of war” across the Generics space

Understanding Modified Release Technologies

(Article)

PAT-based analysis methodologies help see, quality and quantify subtle changes in doasge forms

We Have to Speak the Same Language

(Article)

There were a number of misconceptions (e.g., samples “have” to be ground, since there is no way to account for particle size) that held back method development in Pharma for years.

2013 All-Star Innovators

(Article)

We polled pharma fans to pick their MVPS (Most Valuable Products) from the industry's top tech teams

Sort By Relevance Sort By Date
1 2 3 4 5